MAPT and Alzheimer disease: Prevailing data suggest that abnormal lipid metabolism influences amyloid-beta (Aβ) metabolism and deposition in both the brain parenchyma and vasculature, as well as tau hyperphosphorylation and aggregation, which is then likely to trigger a series of downstream catalytic events that eventually affect the progression of the pathogenesis of AD [36].